We recommend performing multiple tests to improve the positive-predictive and negative-predictive values of preprocedural airway assessment. (Evidence level:High；Recommendation grade:Strong)

We suggest using the minimum set of airway assessment tests that may vary among patients depending on specific underlying pathologies. (Evidence level:Low；Recommendation grade:weak).

For a comprehensive risk assessment, including the postanaesthesia care, the minimum set of airway assessment tests should include, apart from anatomical tests, the evaluation of physiology, environment, devices and the individual and team expertise. (Evidence level:Low；Recommendation grade:Strong).

More evidence is required before recommendations can be made regarding the need for instrumental tests (e.g. ultrasound) for airway assessment. (Evidence level:very Low；Recommendation grade:weak)

In case of predicted and previously experienced difficult airway, we recommend informing the patient adequately and obtaining consent for specific procedures (e.g. awake intubation), and an alert form should be given to the patient in case of future procedures requiring airway management. (Evidence level:Low；Recommendation grade:Strong)

In patients with known chronic kidney disease (CKD), we recommend quantifying the estimated glomerular filtration rate (eGFR) and proteinuria before surgery for risk stratification regarding postoperative acute kidney injury (AKI) and worsening of CKD. (Evidence level:Low；Recommendation grade:Strong)

We suggest considering NT-Pro BNP testing combined with eGFR to add additional information on risk stratification for postoperative acute kidney injury (AKI) and worsening of CKD. (Evidence level:Low；Recommendation grade:weak)

In elective procedures, we suggest that the perioperative continuation of antithrombotic therapy should be weighed against the bleeding risk of surgery, patient-related factors, and the specific antithrombotic medication. (Evidence level:Low；Recommendation grade:weak)

We recommend continuing antiplatelet therapy for 6 months after elective percutaneous intervention and 12 months after an urgent coronary intervention. In the case of drug-coated balloon angioplasty, the duration of dual antiplatelet therapy could vary from a minimum of 1 month to a maximum of 12 months, depending on the status of the disease (stable vs. unstable, chronic vs. acute), the dimension of the occluded vessel, presence of in-stent restenosis, type of stenosed stent and bleeding risk. (Evidence level:Low；Recommendation grade:Strong)

We recommend managing anticoagulant medication before an emergency/urgent procedure based on its pharmacokinetic characteristics, reversal agent availability, the patient's renal function and the likelihood of major bleeding (Evidence level:High；Recommendation grade:Strong)